The SELECT trial on semaglutide (see prior blog) of over 17,000 patients showed sustained improvement in BMI and weight loss. This was another paper presented at the May 2024 European Congress on Obesity, co-published in Nature Medicine.
This second study looked at the relationship between weight change and cardiovascular outcomes. They focused on “the time to first major adverse cardiovascular event” and heart failure.
What Were the Results of the Semaglutide Trial?
- Treatment with semaglutide gave cardiovascular benefits irrespective of starting weight or the amount of weight lost.
- These effects were seen across age, gender, geographic, et al.
- These patients were NOT diabetic.
- “Even patients with relatively mild levels of obesity or those who only lost modest amounts of weight have improved cardiovascular outcomes.”
They postulate that semaglutide has other actions besides weight loss which lower heart disease risk beyond reducing unhealthy body fat. They think it may be stemming from positive impact on blood sugar, lowering blood pressure, helping with inflammation, or a direct effect on heart muscle or blood vessels — or some combination of all factors.
How Can Biohackr Health Help?
We know semaglutide.
If you have any medical issues (blood pressure, heart disease, diabetes, etc.) and your BMI is over 27 (or your BMI is over 30), semaglutide and tirzepatide (or another GLP1 agonist) is good for you. Not only does it lower your BMI, study after study shows it helps with other health issues. This study shows clear, conclusive evidence that semaglutide helps prevent heart issues and blood vessel issues. Heart attacks, strokes, heart failure, and blood pressure are lower when people have taken this medication, and as the study indicated, it didn’t matter how much weight was lost or what weight you started at.
Optimize your heart health.
